Objective: The aim of the study was to determine whether there are differences in the clinical presentation of symptoms and vulvar pain ratings in postmenopausal women compared with premenopausal women with provoked vestibulodynia (PVD) enrolled in a clinical trial, after correcting for estrogen deficiency.
V ulvodynia is a chronic pain disorder of the vulva, defined as ''a vulvar discomfort, most often described as burning pain, occurring in the absence of relevant findings or a specific clinically identified neurologic disorder.'' 1 The International Society for the Study of Vulvar Disease (ISSVD) classifies vulvodynia as generalized (involving the entire or large portions of the area between the mons and anus) or localized (involving a defined area, such as the vestibule or clitoris). Each may be further subdivided into provoked (pain with contact, such as tampon insertion or intercourse), unprovoked (continuous pain present without contact), or both. 1 Vulvodynia may also present as stinging, irritation, itching, pain, or rawness. Provoked vestibulodynia (PVD), the most common form of vulvodynia, is pain with contact to the area immediately anterior to the hymenal ring, known as the vestibule.
Vulvodynia is estimated to affect 8% to 15% of women, [2] [3] [4] and one report described this pain syndrome as the leading cause of dyspareunia in women under the age of 50 years. 5 Vulvodynia, however, has been diagnosed across the lifespan of women. A recent population-based telephone survey of 2,269 women reported a weighted vulvodynia incidence of 8%, which remained stable until the age of 70 years, after which it declined. 6 In this study, peri-and postmenopausal women reported pain symptoms at a similar rate irrespective of hormone therapy, suggesting symptoms may not have been directly cause by estrogen loss changes, and women after the age of 70 years had no decline in prevalence compared with younger women when those women who had had intercourse in the last 6 months were evaluated separately.
Despite these studies, which evaluate the incidence of vulvodynia in peri-and postmenopausal women, little data exist that compare the symptoms of vulvodynia in this population with premenopausal women. It has been postulated that the overlap of symptoms of vulvodynia with the symptoms associated with the genitourinary syndrome of menopause leads to underdiagnosis and subsequent inadequate treatment of vulvodynia in the hormone-deficient woman. 7 Our objective was to determine whether there were differences in the clinical presentation of symptoms and vulvar pain ratings in affected postmenopausal women compared with premenopausal women with PVD enrolled in a clinical trial.
METHODS
Questionnaire data were collected from women enrolled between August 2011 and October 2014 in a multisite, National Institute of Health (NIH)-funded, randomized, double-blind, placebo-controlled crossover study of extended-release gabapentin in the treatment of PVD. Institutional review board approval was obtained at all three study sites: the University of Tennessee Health Science Center, Rutgers Robert Wood Johnson Medical School, and the University of Rochester Medical Center. Women were enrolled in the study if they were older than 18 years; had greater than 3 continuous months of insertional dyspareunia, pain to touch, or both with tampon insertion; modified Freidrich's Criteria for vulvodynia 8 ; and demonstrated an average of 4 or greater on the 11-point tampon test 9 (0 ¼ no pain at all; 10 ¼ worse pain ever) recorded in electronic diaries during the 2-week screening period. Modified Freidrich's criteria were fulfilled if the woman: (1) reported greater than 3 continuous months of vulvar symptoms, including insertional dyspareunia, pain with tampon insertion, or pain to touch; (2) demonstrated on physical examination, moderate-to-severe tenderness to touch, localized to the vulvar vestibule; and (3) demonstrated absence or variable degrees of erythema of the vestibule. The 11-point tampon test is a self-report pain scale caused by pain with tampon insertion, which is shown to be valid and reliable in the diagnosis and monitoring of PVD. 10 Exclusion criteria included: (1) other vulvar conditions or active infections identified clinically or by a positive Affirm test (VPIII microbial identification test); (2) a prior vestibulectomy; (3) pregnant or at risk for pregnancy and not using a reliable contraceptive for 3 months before and during the study; (4) a major medical or psychiatric condition, including substance abuse; (5) a score of greater than or equal to 12 on the depression subscale of the Hospital Anxiety and Depression Scale (HADS), indicating a major depressive episode 9 ; (6) use of centrally acting medications, excluding selective serotonin reuptake inhibitors (SSRIs); and (7) use of topical lidocaine.
At the screening visit, a self-administered questionnaire collected detailed demographic data and a complete medical and gynecologic history, including current medications. Menopausal status was self-reported. A visual inspection of the vulva, speculum examination, and bimanual pelvic examination was performed. A cotton swab test was used to clinically confirm PVD, an Affirm test collected, and a vaginal swab obtained for Rakoff stain evaluation to determine vaginal estrogen status. 11 If the Affirm test was positive for yeast, Gardenerella or trichomonas, the woman was treated and rescreened. Women with Rakoff stain showing greater than 10% parabasal cells were treated with local estrogen, if appropriate, and rescreened after 6 weeks. Women continued the 2-week screening phase only after a negative Affirm test report and a Rakoff with less than 10% parabasal cells was demonstrated.
Women completed a standardized questionnaire at baseline describing their vulvar symptoms and rated daily pain on a visual analog scale (0 ¼ no pain to 10 ¼ worse pain imaginable) from sexual intercourse, tampon insertion (as a surrogate measure of intercourse), and 24-hour vulvar pain during a 2-week screening period using an electronic diary. Pretreatment data were analyzed before pharmacologic intervention. Chi-square was used to determine the differences between pre-and postmenopausal women in demographic characteristics and clinical presentation, and independent t tests were used to analyze pain ratings by (0-10) numeric rating scale (NRS).
VULVODYNIA IN PRE-AND POSTMENOPAUSAL WOMEN

RESULTS
Of the 499 women prescreened by a telephone questionnaire, 149 were screened, 96 were eligible, and 70 completed daily diaries during the 2-week screening period. Two women had greater than or equal to10 parabasal cells and vaginal atrophy at screening and entered the study after 6 weeks of topical hormone therapy. Three other participants were receiving topical hormone therapy at screening. Twenty-five participants who met all other eligibility criteria had vaginitis (diagnosed either with clinical evaluation or with a positive Affirm test) at screening and entered the study after treatment (Fig. 1) . The average ages of pre-and postmenopausal women were (30.6 AE 8.6 y) and (54. (Fig. 1) .
Postmenopausal women were more likely to report burning (70.00% vs 43.42%, P ¼ 0.03), but there were no significant differences, in vulvar itching (20.00% vs 22.37%, P ¼ 0.82), vulvar stinging (40.00% vs 36.84%, P ¼ 0.79), vulvar aching (50.00% vs 63.16%, P ¼ 0.28), vulvar stabbing (60.00% vs 71.06% P ¼ 0.34) (Fig. 2) , or in mean number of symptoms (2.40 AE 1.0 vs 2.37 AE 1.4, P ¼ 0.92). The percentage of postmenopausal women who complained of vulvar burning did not differ with respect to use or nonuse of hormone therapy (80.00% vs 70.59%, P ¼ 1.0).
Of the 70 women completing the 2-week screening diary (54 pre-and 16 postmenopausal) and meeting tampon Two subjects had !10 parabasal cells and vaginal atrophy at screening and entered the study after 6 weeks of topical hormone therapy. Three other participants were receiving topical hormone therapy at screening. 2 Twenty-five participants had vaginitis and entered the study after treatment. 3 Of the 70 participants completing diaries, 16 were postmenopausal and 54 were premenopausal. Of the 43 participants having sexual intercourse, 6 were postmenopausal and 37 were premenopausal.
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insertion pain, there were no significant differences in mean (AESD) NRS pain ratings of postmenopausal compared with premenopausal women for tampon insertion (5.66 AE 1.93 vs 5.83 AE 2.15, P ¼ 0.77) or daily vulvar pain (3.19 AE 2.55 vs 3.83 AE 2.49, P ¼ 0.38). Of the 43 women reporting sexual intercourse (37 pre-and 6 postmenopausal), there were no differences in pain ratings (6.00 AE 2.53 vs 5.98 AE 2.29 AE P ¼ 0.98 (Fig. 2) .
DISCUSSION
Vulvodynia has been shown to both develop and persist in peri-and postmenopausal women, with incidences reported as high as 15.6% in women more than age 65 years. 6 Studies have also shown similar histopathology between pre-and postmenopausal women with vestibulodynia, although the latter had increased lymphocytic infiltration. 12 Despite this interest in postmenopausal vulvodynia, little attention has been paid to the presenting symptoms in this population. Goetsch 13 reported a series of seven postmenopausal women who presented with debilitating vulvar burning, with variable responses to local estrogen therapy, felt to have vulvodynia. Most published demographic data report primary and presenting symptoms, but do not stratify these symptoms in terms of menopausal status. [14] [15] [16] [17] Our data provide a comparison of symptoms of pre-and postmenopausal women identified clinically with PVD who were enrolled in a clinical study. The results suggested that, with the exception of a burning, there is no difference in either type or number of presenting symptoms, daily pain scores or pain with tampon insertion or sexual intercourse in postversus premenopausal women with PVD.
The reason why vulvar burning was more commonly reported in postmenopausal women is unclear. Chronicity of illness may be a contributing factor because approximately 64% of postmenopausal women reported symptom duration of greater than 5 years compared with 49% of premenopausal women (P ¼ 0.09). Age was, however, not a significant predictor of burning. Furthermore, infection and other vulvar pathology had been evaluated, with exclusion from the clinical trial if present and untreated.
The question of whether a hypoestrogenic state could have been the cause of the greater incidence of burning in the postmenopausal population remains unanswered. All women included in the study had a normal maturation index, with less than 10% parabasal cells. Our inclusion of a maturation index as a screening test was to provide an objective uniformity in our sample population, as a measure of vaginal estrogenization, not necessarily to reflect lack of genitourinary symptoms of menopause. Neither of the two women who were placed on local estrogen therapy after identification of an elevated parabasal cell count, however, had symptom improvement or improved cotton swab or 11-point tampon test point scores after parabasal count improved.
It is possible that the more severe chronic inflammation found in postmenopausal tissue 12 may place these women at increased risk for burning, but these relationships have not been explored.
Race should also be considered when interpreting differences in symptoms because race was a significant predictor of burning on multivariate analysis (P < 0.0001). Future studies should evaluate the effect of race on presenting symptoms and pain severity in women with vestibulodynia.
As expected, daily pain was lower than tampon pain insertion and sexual intercourse in both groups, as our population included women with PVD rather than generalized vulvodynia, in which pain is most likely to be continuous.
The strength of our data was that it included only women with absence of vulvar disease on visual inspection or infection by Affirm testing. The use of the 11-point tampon test as a surrogate measure of PVD pain with intercourse allowed comparison of pain in both sexually active and inactive women.
Weaknesses of our study include the use of selfreport measure for vulvodynia symptoms, rather than an instrument specifically designed to measure pain descriptors, which would have provided more word choices and categories of severity. Menopausal status was also selfreported. Another limitation is lack of uniformity of hormone use. However, only 5 of the 22 women were taking HT, and when the two groups were compared, results did not vary. Additionally, the statistical power of our conclusion is limited by the small number of women in the study. Only burning showed significance. In order to detect the differences for other outcome variables with 80% power at 5% significance level, we would have needed to increase the sample size per group to 161 for aching, and more than 1000 for itching, stinging and stabbing symptoms. To detect a difference of 1 in the 11-point tampon test, we would have needed 67 women in each group; however such a minor decrease would not be considered clinically meaningful. The power necessary to detect these differences was from 0.07 to 0.40.
CONCLUSIONS
Pre-and postmenopausal women with PVD have similar pain scores, and, with the exception of a higher prevalence of burning in postmenopausal women, similar presenting clinical symptoms. As burning is often the presenting symptom in women with genitourinary syndrome of menopause, our study suggests a rigorous clinical evaluation for vulvodynia may be warranted in postmenopausal women in whom treatment of presumed symptoms from atrophy does not alleviate symptoms.
